Literature DB >> 24097844

Costs of psychosis in 2010: findings from the second Australian National Survey of Psychosis.

Amanda L Neil1, Vaughan J Carr, Cathrine Mihalopoulos, Andrew Mackinnon, Vera A Morgan.   

Abstract

OBJECTIVES: To estimate the annual costs of psychosis in Australia from societal and government perspectives and assess whether average costs per person differ by principal service provider at time of census.
METHODS: Costs of psychosis encompassing health sector costs, other sector costs, and productivity losses were assessed for 2010 using a prevalence-based, bottom-up approach. Resource use data were obtained from the second Australian National Survey of Psychosis and unit costs were from government and non-government organization (NGO) sources. Costs to society were assessed by principal service provider at census: public specialized mental health services (PSMHS) and NGOs during the census month (current clients), and PSMHS in the 11 months preceding census (recent clients), and any differences were ascertained.
RESULTS: The average annual costs of psychosis to society are estimated at $77,297 per affected individual, comprising $40,941 in lost productivity, $21,714 in health sector costs, and $14,642 in other sector costs. Health sector costs are 3.9-times higher than those for the average Australian. Psychosis costs Australian society $4.91 billion per annum, and the Australian government almost $3.52 billion per annum. There are significant differences between principal service providers for each cost category. Current PSMHS clients had the highest health sector costs overall, and the highest mental health ambulatory, inpatient, and antipsychotic medication costs specifically. NGO clients had the highest other sector costs overall and the highest NGO assistance, supported employment, and supported accommodation costs. Recent PSMHS clients had the lowest productivity losses for reduced participation and the highest costs for absenteeism and presenteeism.
CONCLUSIONS: The costs of psychosis are broad ranging and very high. Development and implementation of cost-effective prevention, treatment, and support strategies is critical to maximizing the efficiency of service delivery. A needs-based framework based on principal service provider and recency of contact may facilitate this process.

Entities:  

Keywords:  Australia; cost of illness; psychotic disorders; schizophrenia

Mesh:

Year:  2013        PMID: 24097844     DOI: 10.1177/0004867413500352

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  10 in total

1.  Four-Year Cost-effectiveness of Cognitive Behavior Therapy for Preventing First-episode Psychosis: The Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial.

Authors:  Helga K Ising; Joran Lokkerbol; Judith Rietdijk; Sara Dragt; Rianne M C Klaassen; Tamar Kraan; Nynke Boonstra; Dorien H Nieman; David P G van den Berg; Don H Linszen; Lex Wunderink; Wim Veling; Filip Smit; Mark van der Gaag
Journal:  Schizophr Bull       Date:  2017-03-01       Impact factor: 9.306

2.  Prevalence, Employment Rate, and Cost of Schizophrenia in a High-Income Welfare Society: A Population-Based Study Using Comprehensive Health and Welfare Registers.

Authors:  Stig Evensen; Torbjørn Wisløff; June Ullevoldsæter Lystad; Helen Bull; Torill Ueland; Erik Falkum
Journal:  Schizophr Bull       Date:  2015-10-03       Impact factor: 9.306

3.  Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT.

Authors:  Andrew I Gumley; Simon Bradstreet; John Ainsworth; Stephanie Allan; Mario Alvarez-Jimenez; Maximillian Birchwood; Andrew Briggs; Sandra Bucci; Sue Cotton; Lidia Engel; Paul French; Reeva Lederman; Shôn Lewis; Matthew Machin; Graeme MacLennan; Hamish McLeod; Nicola McMeekin; Cathy Mihalopoulos; Emma Morton; John Norrie; Frank Reilly; Matthias Schwannauer; Swaran P Singh; Suresh Sundram; Andrew Thompson; Chris Williams; Alison Yung; Lorna Aucott; John Farhall; John Gleeson
Journal:  Health Technol Assess       Date:  2022-05       Impact factor: 4.106

4.  Improvements in Hope, Engagement and Functioning Following a Recovery-Focused Sub-Acute Inpatient Intervention: a Six-Month Evaluation.

Authors:  Tanya M Hollier; Barry G Frost; Patricia T Michie; Terry J Lewin; Ketrina A Sly
Journal:  Psychiatr Q       Date:  2021-06-14

5.  Improving treatments for psychotic disorders: beyond cognitive behaviour therapy for psychosis.

Authors:  B Nelson; L Torregrossa; A Thompson; L A Sass; S Park; J A Hartmann; P D McGorry; M Alvarez-Jimenez
Journal:  Psychosis       Date:  2020-06-19

6.  Cost-utility analysis of rTMS as add-on therapy to standard care for the treatment of hallucinations in schizophrenia.

Authors:  Lauren Hendriks; Cathrine Mihalopoulos; Long Khanh-Dao Le; Colleen Loo; Mary Lou Chatterton
Journal:  Eur Psychiatry       Date:  2022-03-30       Impact factor: 7.156

7.  Global economic burden of schizophrenia: letter in response.

Authors:  Amanda L Neil; Vaughan J Carr
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-05       Impact factor: 2.570

8.  An Integrated Recovery-oriented Model (IRM) for mental health services: evolution and challenges.

Authors:  Barry G Frost; Srinivasan Tirupati; Suzanne Johnston; Megan Turrell; Terry J Lewin; Ketrina A Sly; Agatha M Conrad
Journal:  BMC Psychiatry       Date:  2017-01-17       Impact factor: 3.630

9.  Health-economic benefits of treating trauma in psychosis.

Authors:  Paul A J M de Bont; Berber M van der Vleugel; David P G van den Berg; Carlijn de Roos; Joran Lokkerbol; Filip Smit; Ad de Jongh; Mark van der Gaag; Agnes van Minnen
Journal:  Eur J Psychotraumatol       Date:  2019-01-21

10.  Cost-Effectiveness of Virtual Reality Cognitive Behavioral Therapy for Psychosis: Health-Economic Evaluation Within a Randomized Controlled Trial.

Authors:  Roos Pot-Kolder; Wim Veling; Chris Geraets; Joran Lokkerbol; Filip Smit; Alyssa Jongeneel; Helga Ising; Mark van der Gaag
Journal:  J Med Internet Res       Date:  2020-05-05       Impact factor: 5.428

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.